# A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

> **NCT06004960** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 6 (actual)

## Conditions studied

- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

## Interventions

- **DRUG:** [14C]CCX168

## Key facts

- **NCT ID:** NCT06004960
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-20
- **Primary completion:** 2014-12-05
- **Final completion:** 2014-12-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004960, "A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06004960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*